Literature DB >> 20477689

Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis.

Friedrich Horak1, Ursula Petra Zieglmayer.   

Abstract

Rhinitis affects millions of people around the world, places a huge burden on the economy and reduces patients' health-related quality of life. Azelastine nasal spray is a second-generation antihistamine, indicated for the treatment of allergic and nonallergic rhinitis in both adults and children. It offers a rapid onset of action (15 min) and flexibility of both dose (i.e., one or two sprays/nostril twice daily) as well as dosage (i.e., fixed or as needed). Compared with other agents used to treat allergic rhinitis, azelastine nasal spray exhibits superior efficacy to oral antihistamines (e.g., desloratadine and cetirizine), other intranasal antihistamines (e.g., levocabastine) and the intranasal corticosteroid mometasone furoate, and comparable efficacy to the potent intranasal corticosteroid fluticasone propionate (FP). Combination therapy with intranasal FP has the potential to enhance clinical benefit, as the combination of azelastine and FP nasal sprays reduce symptoms in allergic rhinitis patients more than either agent alone. Azelastine nasal spray has an excellent safety profile.

Entities:  

Year:  2009        PMID: 20477689     DOI: 10.1586/eci.09.38

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  8 in total

1.  Treatment of allergic rhinitis with ectoine containing nasal spray and eye drops in comparison with azelastine containing nasal spray and eye drops or with cromoglycic Acid containing nasal spray.

Authors:  Nina Werkhäuser; Andreas Bilstein; Uwe Sonnemann
Journal:  J Allergy (Cairo)       Date:  2014-06-01

Review 2.  An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel.

Authors:  Brian Lipworth; Jon Newton; Bhaskar Ram; Iain Small; Jürgen Schwarze
Journal:  NPJ Prim Care Respir Med       Date:  2017-01-23       Impact factor: 2.871

3.  Catgut Implantation at Acupoint Reduces Immune Reaction in a Rat Model of Allergic Rhinitis.

Authors:  Shasha Yang; Jing Wu; Qinxiu Zhang; Xinrong Li; Daien Liu; Bin Zeng; Hongjiao Gao; Xiaolin Yan; Zhendong Zhong
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-05       Impact factor: 2.629

Review 4.  Towards definitive management of allergic rhinitis: best use of new and established therapies.

Authors:  Lubnaa Hossenbaccus; Sophia Linton; Sarah Garvey; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2020-05-27       Impact factor: 3.406

5.  Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).

Authors:  Mustafa Cenk Ecevit; Müge Özcan; İlknur Haberal Can; Emel Çadallı Tatar; Serdar Özer; Erkan Esen; Doğan Atan; Sercan Göde; Çağdaş Elsürer; Aylin Eryılmaz; Berna Uslu Coşkun; Zahide Mine Yazıcı; Mehmet Emre Dinç; Fatih Özdoğan; Kıvanç Günhan; Nagihan Bilal; Arzu Yasemin Korkut; Fikret Kasapoğlu; Bilge Türk; Ela Araz Server; Özlem Önerci Çelebi; Tuğçe Şimşek; Rauf Oğuzhan Kum; Mustafa Kemal Adalı; Erdem Eren; Nesibe Gül Yüksel Aslıer; Tuba Bayındır; Aslı Çakır Çetin; Ayşe Enise Göker; Işıl Adadan Güvenç; Sabri Köseoğlu; Gül Soylu Özler; Ethem Şahin; Aslı Şahin Yılmaz; Ceren Güne; Gökçe Aksoy Yıldırım; Bülent Öca; Mehmet Durmuşoğlu; Yunus Kantekin; Süay Özmen; Gözde Orhan Kubat; Serap Köybaşı Şanal; Emine Elif Altuntaş; Adin Selçuk; Haşmet Yazıcı; Deniz Baklacı; Atılay Yaylacı; Deniz Hancı; Sedat Doğan; Vural Fidan; Kemal Uygur; Nesil Keleş; Cemal Cingi; Bülent Topuz; Salih Çanakçıoğlu; Metin Önerci
Journal:  Turk Arch Otorhinolaryngol       Date:  2021-05

6.  A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis.

Authors:  Anne K Ellis; Yifei Zhu; Lisa M Steacy; Terry Walker; James H Day
Journal:  Allergy Asthma Clin Immunol       Date:  2013-05-01       Impact factor: 3.406

7.  Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score.

Authors:  Mark W Tenn; Lisa M Steacy; Charlene C Ng; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2018-01-16       Impact factor: 3.406

Review 8.  Metabolic N-Dealkylation and N-Oxidation as Elucidators of the Role of Alkylamino Moieties in Drugs Acting at Various Receptors.

Authors:  Babiker M Eh-Haj
Journal:  Molecules       Date:  2021-03-29       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.